IMTX ▼ -3.1% - Immatics N.V. $IMTX - Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting 24-OCT-2026 02:30 AM ET